Retrotopeae S Proprietary Drug Platform Represents A Breakthrough In Thetreatment Of Degenerativediseasesresearch Has Established A Link Between Theoxidativedamageof Lipids In Mitochondrial Membranes And Neurodegeneration In Parkinson Salzheimer Sfriedreich S Ataxia And Other Diseases Retrotopes First Drug Candidatert001Confers Cell Protection Against Oxidativestress In High Energy Tissues Likebrainretina And Heart Tissueby Inhibiting Mitochondrial Lipid Peroxidationits Mechanism Of Action Has Been Shown Not Only To Prevent Further Cellular Damagebut Also To Recover Mitochondrial Functionrt001 S Molecular Structureis So Similar To Ordinary Fats That Thebody Naturally Distributes Them Throughout Thetissues Wherever They Areneededthedrug Has Been Determined Safein Human Trials In A Recent Phase1 2 Clinical Trial In Friedreich S Ataxia Patients Retrotopeis A Privately Held Company Founded And Backed By Worldaerenowned Scientistsentrepreneursand Investors Thecompany Founders Havedozens Of Years Of Experiencein Drug Discovery Technologiesa Member Of Theus National Academy Of Sciencesand Several Successful Startups Among Them Retrotopehas Developed Its Sciencevirtuallywith Over 50 Collaborations At Major Centers Of Excellencearound Theworld That Haveyielded Insights Into Themechanisms Of Several Diseases
